Eltoprazine - Elto Pharma

Drug Profile

Eltoprazine - Elto Pharma

Alternative Names: DU-28853; Eltoprazine

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Developer Elto Pharma; PsychoGenics; Solvay
  • Class Antidepressants; Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Aggression; Drug-induced dyskinesia
  • No development reported Cognition disorders
  • Discontinued Psychotic disorders

Most Recent Events

  • 20 Jul 2018 Elto Pharma expects to initiate the phase IIb trial for Parkinson's disease levadopa-induced dyskinesia in the first half of 2019
  • 01 May 2018 The Canadian Intellectual Property Office issues a Notice of Allowance for a patent application in non-Attention-deficit hyperactivity disorder neurological and mental disorders, including Parkinson's disease and Alzheimer's disease
  • 12 Apr 2018 Amarantus Bioscience plans a phase IIb trial in Parkinson's disease levadopa-induced dyskinesia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top